Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | SPICE trial: enadenotucirev with nivolumab in tumors of epithelial origin

Marwan Fakih • 29 Sep 2019
ESMO 2019
General Antibodies Enadenotucirev Nivolumab

Marwan Fakih, MD, City of Hope Comprehensive Cancer Center, Duarte, CA, talks about the rationale behind the SPICE study (NCT02636036) of enadenotucirev in combination with nivolumab in tumors of epithelial origin. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Marwan Fakih

4:06
AMG 510 for targeting KRAS G12C mutant solid tumours
Marwan Fakih • 29 Sep 2019

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals